Should Your Dog Be on Peptides?
Summary
Bloomberg’s Big Take explores the booming pet longevity industry, where owners like Sam Chow use human biohacking trends such as rapamycin and peptides to extend their dogs' lives. Reporter Anika Anampudi examines this $165 billion market, highlighting the surge in preventative care and supplements driven by the pandemic. The episode weighs the emotional desire for "good years" against the lack of conclusive scientific evidence and significant costs.
Topics discussed
Sponsors: ChatGPT Work, Cincinnati Insurance, and Michigan
Sam Chow's extreme pet wellness routine and biohacking
The booming $165 billion US pet spending industry
Sam Chow's life, dogs, and linked human-pet self-care
Market growth in pet supplements and Rapamycin trials
Why owners try unproven treatments for shorter-lived pets
Industry efforts: Loyal Animal Health and Elanco research
Tech Minute: The $30 billion sleep support industry
Sponsors: Instagram Teen Accounts and BMW Certified
Rapamycin regulations and the 'Longevity Vet'
Veterinary caution on Rapamycin efficacy and safety
Ethics of experimenting on pets for longevity
Sam Chow's $8,000 annual spend and cryonics interest
Outro and Sponsors: Adeio CRM and Venmo Debit Card
Listen ad-free on Castria